Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.25% | -597.53% | -176.40% | -508.91% | 871.52% |
| Total Depreciation and Amortization | -44.44% | -46.43% | -41.51% | -3.70% | 3.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.66% | 332.06% | 157.35% | 1,551.98% | -634.32% |
| Change in Net Operating Assets | -220.94% | -151.44% | 103.32% | -10.40% | 167.22% |
| Cash from Operations | -270.28% | -138.41% | -34.77% | -923.20% | 178.82% |
| Capital Expenditure | -- | -50.00% | -266.67% | 84.38% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.95% | -21.27% | -48.55% | 54.38% | 744.35% |
| Cash from Investing | -157.95% | -21.27% | -48.58% | 54.39% | 743.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -64,450.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.79% | -- | 95.22% | -101.73% | -- |
| Foreign Exchange rate Adjustments | 1,100.00% | 0.00% | -125.00% | 109.68% | -157.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.73% | 111.07% | 243.35% | -3,183.22% | 481.71% |